What is Xheme?
Xheme Inc operates at the intersection of advanced material science and biotechnology, specializing in the development of innovative polymer composite technologies. By engineering materials that actively reduce oxidative stress, the company enhances the performance and vitality of biological cells, a critical requirement for modern cell therapeutic production and the storage of vital fluids. Their market position is defined by a commitment to sustainable, programmable design, which allows for high-performance applications in bioprocessing. By prioritizing safety and environmental stewardship, Xheme is effectively disrupting the traditional biomedical plastics sector, offering solutions that are both technically superior and ecologically responsible.
How much funding has Xheme raised?
Xheme has raised a total of $40K across 1 funding round:
Stock/Share Issuance
$40K
Stock/Share Issuance (2025): $40K, investors not publicly disclosed
Key Investors in Xheme
Undisclosed Investor
An undisclosed institutional partner providing strategic backing to support the company's long-term growth and operational scaling.
What's next for Xheme?
The infusion of capital will likely accelerate Xheme's strategic roadmap, focusing on the commercialization of its core composite technologies and the expansion of its collaborative ecosystem. As the company moves beyond its current Series B/C stage, management is expected to prioritize the scaling of manufacturing capabilities to meet the rising demand in the cell therapy market. Furthermore, the firm is poised to deepen its industry partnerships, leveraging its open innovation model to integrate its materials into broader clinical and industrial workflows. This phase of development will be critical in establishing Xheme as a foundational player in the global bioprocessing supply chain, ensuring that their advancements in cell vitality translate into tangible improvements in patient outcomes and sustainable manufacturing practices.
See full Xheme company page
